Skip to main content
News and Products

Improved quantitative accuracy in PET

By 5th March 2014No Comments

GE Healthcare’s  Q.Clear technology provides up to two times improvement in PET quantitative accuracy (SUVmean) and image quality (signal-to-noise ratio). This enables clinicians to quickly and confidently evaluate a patient’s response to cancer treatment. The new technology shows the advantage of full convergence PET imaging without compromise between quantitation and image quality.

In the field of oncology, PET/CT imaging can be an invaluable diagnostic tool for monitoring cancer treatment. It can also help clinicians tailor a regimen of therapies to fit their patients’ individual needs. GE Healthcare’s Discovery 710 Elite is designed to enable a whole new level of performance by incorporating high sensitivity and low dose innovations with new quantitative tools that generate more consistent PET measurements, enabling clinicians to more accurately assess treatment response to support more personalized care, into a premium platform.

Studies have shown that sometimes 6 cycles of chemotherapy are required to determine if the treatment is effective for patients. This can lead to the cost of a patient’s chemotherapy drugs alone reaching  € 80,000 a year. Other data show that 70% of cancer patients to not respond to their initial chemotherapy treatment.

If clinicians have a more accurate, reliable and faster tool to determine treatment efficacy sooner it may help confirm that a change in treatment is needed, enabling clinicians to adjust their approach, reducing the cost of ineffective therapy and improving the patient’s quality of life. For example, PET/CT can help clinicians determine whether chemotherapy is working after as few as one to two cycles, potentially saving patients unnecessary procedures and a significant amount of money. The Q.Clear system gives clinicians the ability to help make that determination. Coupled with Q.Suite, which introduces the importance of eliminating variability such as respiratory motion, Q.Clear should enable clinicians to assess treatment response more accurately

GE Healthcare

Chalfont St Giles, England, UK